Alphatec Holdings logo
Alphatec Holdings ATEC
$ 8.26 0.61%
report update icon

Quarterly report 2026-Q1
added 05-05-2026

Alphatec Holdings Financial Ratios 2025-2011 | ATEC

Brief overview of Alphatec Holdings's valuation and returns

The comparison uses the five latest available annual observations between 2021 and 2025.

The current valuation set is P/S 2.7x (median 3.87x), P/B 2.61x (median 2.32x). The multiple basket looks neutral against its history, differing from median levels by roughly -8.6%.

Capital efficiency is characterized by ROE -11.5%, ROA -18.1%, ROCE -6.6%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.

Current PEG is 0.65x; the market pays comparatively little per unit of expected growth.

The time from paying for inputs to receiving cash fell from 250.6 days to 240.1 days. Cash turnover improved.

Conclusion

Alphatec Holdings's market valuation is near its own historical norm, while quality ratios provide no extreme signal.

Annual Financial Ratios Alphatec Holdings

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-14.4 -9.6 -10.0 -10.1 -7.4 -13.6 -6.4 -1.9 -18.4 -0.8 -0.2 -9.7 -2.6 -9.9 -7.2

P/S

2.7 2.5 3.9 4.3 4.4 7.4 3.2 0.6 0.4 0.2 0.2 0.6 1.0 0.8 0.8

EPS

-1.0 -1.1 -1.5 -1.5 -1.5 -1.2 -1.1 -1.2 -0.2 -3.5 -1.8 -0.1 -0.8 -0.2 -0.2

EV (Enterprise Value)

1.91 B 1.41 B 1.64 B 1.44 B 873 M 968 M 443 M 137 M 131 M 141 M 214 M 301 M 387 M 267 M 261 M

EBITDA per Share

-0.03 -0.4 -0.97 -1.02 -1.05 -0.71 -0.727 -0.545 -0.545 -1.23 -0.268 0.895 -1.63 -0.642 -1.56

EV/EBITDA

-8.6 -19.8 -9.8 -3.7 -8.7 -5.0 -49.9 25.8 -19.0 -35.8 -14.6

PEG

0.65 2.29 -0.7 -0.66 -1.58 -0.2 -0.7 0.0 -0.19 -0.01 0.0 -0.11 0.01 -0.31 0.19

P/B

2.6 2.0 2.3 2.9 1.9 4.1 8.3 3.1 -1.6 -0.6 -1.1 0.8 1.3 0.6 0.7

P/CF

45.7 -34.8 -23.8 -20.3 -14.5 -23.2 -7.9 -1.7 -2.6 -1.3 -19.7 -3.9 -29.4 -26.4 35.6

ROE %

-1153.69 1144.21 -238.92 436.42 -177.30 -60.82 -130.65 -164.87 8.61 72.10 488.51 -8.65 -47.90 -6.29 -9.04

ROA %

-18.12 -20.90 -23.18 -29.04 -25.00 -30.24 -33.54 -22.38 -2.71 -31.77 -121.79 -3.73 -22.49 -4.05 -6.05

ROCE %

-660.94 961.03 -221.97 423.96 -158.73 -45.32 -28.95 -20.22 -13.94 -21.00 -28.54 0.91 -6.22 -2.69 -4.41

Current Ratio

- - - - - - 3.0 2.5 2.2 1.8 0.8 1.8 1.4 2.1 2.0

DSO

43.1 46.4 50.2 53.0 49.1 50.0 52.0 61.5 53.2 56.2 75.5 71.3 73.8 76.3 77.0

DIO

270.8 304.1 252.8 299.3 294.1 348.3 355.0 369.0 252.8 249.0 257.2 246.4 194.6 257.2 207.5

DPO

73.8 99.4 88.8 93.7 92.6 109.3 79.2 56.4 35.9 72.0 81.1 59.8 50.1 98.9 78.6

Operating Cycle

313.9 350.5 303.0 352.4 343.2 398.3 407.0 430.4 306.0 305.2 332.6 317.7 268.4 333.4 284.5

Cash Conversion Cycle

240.1 251.2 214.2 258.7 250.6 289.0 327.8 374.0 270.0 233.2 251.5 257.9 218.3 234.5 205.9

All numbers in USD currency

Quarterly Financial Ratios Alphatec Holdings

2026-Q1 2025-Q4 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.22 - -0.27 -0.35 - -0.28 -0.29 -0.34 - -0.35 -0.43 -0.4 - -0.35 -0.36 -0.43 - -0.43 -0.39 -0.26 - -0.24 -0.25 -0.33 - -0.26 -0.27 -0.29 - -0.22 -0.21 -0.09 - -0.23 -0.24 -0.61 -0.49 -1.6 -0.05 -0.07 -0.1 -1.61 -0.04 -0.05 - -0.03 -0.03 -0.07 -0.62 -0.15 -0.05 -0.03 -0.06 -0.03 -0.07 -0.01 -0.18 -0.01 -0.03 -0.02

EBITDA per Share

-0.02 - 0.01 -0.17 - -0.12 -0.14 -0.18 - -0.23 -0.34 -0.26 - -0.26 -0.27 -0.32 - -0.17 -0.31 -0.17 - -0.08 -0.1 -0.25 - -0.11 -0.15 -0.2 - -0.06 -0.09 0.06 - 0.31 0.27 -0.17 - 0.68 0.83 0.05 - -18.2 0.07 0.05 - 0.16 0.12 - - 0.07 0.1 0.05 - 0.17 0.09 0.06 - 0.14 0.07 0.03

ROE %

348.34 2795.98 5704.64 5639.99 2541.78 2638.37 -173.71 246.53 353.66 529.76 609.26 120.53 -228.25 -266.75 -481.35 -193.00 -77.55 -89.61 -63.17 -57.45 -40.19 -73.57 -94.90 -111.23 -91.61 -144.84 -164.69 -176.45 -104.40 -92.63 -27.63 22.75 42.57 53.06 74.36 76.85 72.10 88.69 493.80 491.98 488.51 461.25 21.04 8.30 -8.65 -43.65 -50.06 -50.83 -47.90 -14.89 -7.47 -7.35 -6.32 -10.65 -10.15 -8.79 -9.04 -0.53 -1.24 -0.76

ROA %

-21.26 -17.13 -22.44 -22.52 -16.86 -23.23 -24.28 -27.17 -22.18 -29.31 -30.07 -29.66 -22.66 -29.85 -22.16 -30.82 -21.52 -27.52 -26.32 -23.71 -19.98 -28.55 -31.13 -32.39 -23.52 -30.74 -29.40 -27.55 -14.17 -17.88 -14.36 -12.08 -13.41 -18.03 -28.89 -31.26 -31.77 -33.92 -128.86 -126.00 -122.10 -115.41 -6.77 -4.92 -3.73 -20.18 -23.26 -23.70 -22.49 -7.37 -4.05 -4.44 -4.05 -7.00 -6.71 -5.87 -6.05 -0.36 -0.83 -0.51

ROCE %

363.76 2471.01 4945.54 4794.24 2152.77 2239.63 -148.03 235.41 333.09 500.46 580.97 108.79 -222.62 -254.05 -452.84 -174.51 -65.76 -75.66 -54.14 -45.98 -32.20 -58.78 -75.46 -90.74 -75.12 -117.99 -134.27 -147.65 -83.90 -79.17 -31.58 8.42 20.24 31.20 37.43 35.44 20.02 470.25 909.52 916.48 454.83 456.00 6.93 0.44 -0.76 -8.43 -17.27 -20.19 -10.15 -10.98 -4.14 -3.98 -2.41 -3.37 -3.50 -3.32 -3.27 -0.96 -1.35 -0.96

DSO

48.4 - 45.6 46.5 - 49.2 54.1 53.1 - 48.0 47.7 51.2 - 25.8 21.9 53.0 - 48.9 43.6 51.0 - 52.1 72.5 60.1 - 50.5 53.9 58.1 - 59.9 62.5 64.1 - 58.5 55.5 54.4 62.4 63.2 52.4 60.5 70.5 93.9 75.0 73.9 68.8 72.3 69.4 75.9 71.2 75.2 74.0 74.5 71.0 79.9 77.6 77.9 76.9 79.9 74.8 -

DIO

291.5 - 275.4 296.9 - 337.9 345.3 321.5 - 299.2 198.8 247.4 - 153.7 157.6 400.7 - 351.5 310.3 384.6 - 352.0 477.7 406.1 - 343.2 377.1 363.4 - 386.2 404.6 399.5 - 290.0 288.5 233.8 - 253.1 247.8 294.5 - 352.8 218.6 257.8 - 266.9 229.5 247.4 - 149.9 206.8 242.5 - 270.1 257.5 268.7 - 246.4 203.5 -

DPO

71.3 - 69.5 78.7 - 125.8 141.3 121.3 - 112.0 72.1 87.0 - 50.2 54.1 125.6 - 116.2 121.1 163.8 - 134.7 182.8 127.4 - 76.5 84.1 69.5 - 59.1 61.9 59.0 - 41.2 41.0 51.2 - 73.2 71.6 104.4 - 126.1 69.0 72.3 - 64.8 55.7 61.9 - 38.6 53.2 68.8 - 82.5 78.7 91.5 - 93.3 77.1 -

Operating Cycle

339.9 - 320.9 343.4 - 387.1 399.4 374.7 - 347.2 246.5 298.6 - 179.5 179.5 453.7 - 400.4 353.9 435.6 - 404.1 550.2 466.2 - 393.6 431.1 421.5 - 446.1 467.1 463.6 - 348.6 344.0 288.1 62.4 316.4 300.2 355.0 70.5 446.6 293.6 331.7 68.8 339.3 298.9 323.3 71.2 225.1 280.9 317.1 71.0 350.0 335.1 346.6 76.9 326.4 278.4 -

Cash Conversion Cycle

268.6 - 251.4 264.8 - 261.3 258.1 253.4 - 235.2 174.4 211.6 - 129.2 125.4 328.1 - 284.2 232.8 271.8 - 269.5 367.4 338.8 - 317.1 347.0 351.9 - 387.0 405.2 404.6 - 307.4 303.0 236.9 62.4 243.2 228.5 250.6 70.5 320.5 224.6 259.4 68.8 274.5 243.2 261.5 71.2 186.6 227.7 248.3 71.0 267.4 256.4 255.0 76.9 233.0 201.3 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Alphatec Holdings, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
LENSAR LENSAR
LNSR
$ 5.6 -2.78 % $ 67 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Outset Medical Outset Medical
OM
$ 4.04 -4.49 % $ 61.5 K usaUSA
AxoGen AxoGen
AXGN
$ 39.49 -0.6 % $ 1.82 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 163.26 3.08 % $ 11.5 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.67 -6.38 % $ 156 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 60.45 -2.74 % $ 9.18 B usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 1.42 -6.58 % $ 3.94 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.69 -2.81 % $ 32.4 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 27.48 0.15 % $ 629 M usaUSA
TransMedics Group TransMedics Group
TMDX
$ 72.26 1.59 % $ 2.46 B usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.89 -3.38 % $ 15.1 M usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 17.12 1.3 % $ 1.16 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.12 -2.55 % $ 400 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.77 0.86 % $ 458 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 0.04 % $ 1.16 B usaUSA
Beyond Air Beyond Air
XAIR
$ 5.16 -5.67 % $ 42.8 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 -0.39 % $ 60 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.36 -0.39 % $ 22.4 M usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Inogen Inogen
INGN
$ 6.15 -2.69 % $ 164 M usaUSA